Navigation Links
Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Through 2012
Date:12/3/2008

WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the diagnosis and drug treatment of Alzheimer's disease in China is extremely low and will remain low through 2012, particularly in rural regions. Although rural cases of Alzheimer's disease will account for approximately 70 percent of the prevalent Alzheimer's disease population in China in 2012, less than 10 percent of cases will be diagnosed and even fewer will be treated with approved Alzheimer's disease products.

"Public and professional awareness and prioritization of Alzheimer's disease in China is poor," stated Jonathan Searles, analyst at Decision Resources. "Patients and caregivers -- and even physicians -- across the nation consider Alzheimer's a natural part of aging and largely untreatable. Coupled with the severe stigma attached to the disease and the high cost of approved therapies, market opportunities for Alzheimer's disease therapies in China will remain constrained."

The new Emerging Markets report entitled Alzheimer's Disease in China also finds that the Chinese Alzheimer's disease drug market will continue to stay untapped and underserved despite growing use of approved therapies. Huperzine A (Chinese brands) and donepezil (Eisai's Aricept, Chinese brands) dominated the treatment of Alzheimer's disease, together capturing nearly 80 percent market share in 2007.

In spite of the continued dominance of costly therapies, including growing use of memantine (Lundbeck's Ebixa) -- the most recently-launched and most expensive Alzheimer's disease therapy in China -- the Chinese Alzheimer's drug market is expected to reach a mere $33 million in 2012, due chiefly to the limited pool of treated patients and competition from older, entrenched medicines.

"Ultimately, patients and physicians in China -- especially in rural regions -- will continue to rely heavily on more affordable and more familiar traditional Chinese medicines, such as ginkgo leaf extracts, if pharmacological therapy is sought at all," added Mr. Searles.

EMERGING MARKETS REPORTS

The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumers Uncertain About Their Medical Diagnosis & Treatment
2. SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
3. Med school discovery could lead to better cancer diagnosis, drugs
4. Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue
5. 3 clinical features identified to avoid misdiagnosis of TIAs
6. Wisconsin Health System Installs Computer System for Diagnosis Support
7. More People Living Longer After Cancer Diagnosis
8. Head Injury in Young Kids May Predict ADHD Diagnosis
9. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
10. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
11. Other Health Problems Can Delay MS Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
Breaking Medicine Technology: